Trending...
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
- ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
PHILADELPHIA, April 14, 2025 ~ A team of researchers at Children's Hospital of Philadelphia (CHOP) has made a significant breakthrough in the understanding of neuroblastoma, a common and potentially deadly childhood cancer. Led by senior study author Kai Tan, PhD, the team developed a longitudinal atlas of neuroblastoma to gain deeper insights into the molecular mechanisms underlying treatment resistance.
Published in the journal Nature Genetics, the study offers valuable new insights that could potentially lead to personalized medicine approaches in neuroblastoma treatment. Despite significant advances in standard care, the 5-year survival rate for high-risk neuroblastoma remains less than 50%. One of the major challenges in treating this cancer is its heterogeneity, with different cells within the same tumor exhibiting varying characteristics.
The lack of understanding about how these cells interact and change during treatment has been a major barrier in developing effective therapies. In this study, researchers created a cell atlas that provided an in-depth look at how different cell types, such as malignant cells and immune cells, interact and change within their natural environment.
More on The PennZone
"Our atlas provides a crucial foundation for developing novel treatments by mapping the complex interactions between malignant cells and surrounding cells that support tumor growth," said Dr. Tan. "As researchers, we look to use these insights to tailor therapies to target unique characteristics of a patient's tumor. Overall, we are optimistic about the doors our research and techniques are opening."
To create this atlas, CHOP researchers used advanced single-cell sequencing and spatial omics techniques to analyze tumor samples from 22 pediatric patients with high-risk neuroblastoma before and after chemotherapy. This multidimensional dataset is now available on the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN) data portal.
The team uncovered diverse characteristics of both tumor and non-tumor cells, as well as major changes in these characteristics following chemotherapy. They found that patients had worse outcomes when cancer cells were multiplying more actively and became more metabolically active. On the other hand, tumors that developed more mature, neuron-like features resulted in better outcomes for patients.
Additionally, the researchers found that an increase in a type of mesenchymal-like tumor cells was linked to poorer responses to chemotherapy. They also discovered that certain immune cells, such as macrophages, became more active in ways that promoted tumor growth by enabling blood vessel growth while suppressing the immune response.
More on The PennZone
One of the most significant findings of the study was a specific communication pathway between macrophages and cancer cells (HB-EGF/ERBB4) that triggered signals promoting tumor growth. This highlights the importance of identifying new factors within the tumor microenvironment that influence treatment response. The team is now conducting further studies using preclinical models to test this pathway and potentially develop novel therapeutic strategies.
"This study would not have been possible without the monumental team efforts of biologists, clinicians, and computational scientists," said lead author Wenbao Yu, PhD. "With their collaboration, we were able to gain new insights into the complex ecosystem of neuroblastoma."
The research was supported by a grant from the National Cancer Institute (NCI) Human Tumor Atlas Network (#U2C CA233285), as well as grants from the National Institutes of Health (NIH) (U54 HL165442), American Cancer Society Institutional Research Grant (IRG-22-150-41-IRG), and NIH (T32 CA009140).
This groundbreaking study, titled "Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring," was published online on April 14th, 2025 in Nature Genetics. The DOI for this article is 10.1038/s41588-025-02158-6.
Published in the journal Nature Genetics, the study offers valuable new insights that could potentially lead to personalized medicine approaches in neuroblastoma treatment. Despite significant advances in standard care, the 5-year survival rate for high-risk neuroblastoma remains less than 50%. One of the major challenges in treating this cancer is its heterogeneity, with different cells within the same tumor exhibiting varying characteristics.
The lack of understanding about how these cells interact and change during treatment has been a major barrier in developing effective therapies. In this study, researchers created a cell atlas that provided an in-depth look at how different cell types, such as malignant cells and immune cells, interact and change within their natural environment.
More on The PennZone
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
- IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
- Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
"Our atlas provides a crucial foundation for developing novel treatments by mapping the complex interactions between malignant cells and surrounding cells that support tumor growth," said Dr. Tan. "As researchers, we look to use these insights to tailor therapies to target unique characteristics of a patient's tumor. Overall, we are optimistic about the doors our research and techniques are opening."
To create this atlas, CHOP researchers used advanced single-cell sequencing and spatial omics techniques to analyze tumor samples from 22 pediatric patients with high-risk neuroblastoma before and after chemotherapy. This multidimensional dataset is now available on the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN) data portal.
The team uncovered diverse characteristics of both tumor and non-tumor cells, as well as major changes in these characteristics following chemotherapy. They found that patients had worse outcomes when cancer cells were multiplying more actively and became more metabolically active. On the other hand, tumors that developed more mature, neuron-like features resulted in better outcomes for patients.
Additionally, the researchers found that an increase in a type of mesenchymal-like tumor cells was linked to poorer responses to chemotherapy. They also discovered that certain immune cells, such as macrophages, became more active in ways that promoted tumor growth by enabling blood vessel growth while suppressing the immune response.
More on The PennZone
- P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
- Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
- Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
- Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
- K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
One of the most significant findings of the study was a specific communication pathway between macrophages and cancer cells (HB-EGF/ERBB4) that triggered signals promoting tumor growth. This highlights the importance of identifying new factors within the tumor microenvironment that influence treatment response. The team is now conducting further studies using preclinical models to test this pathway and potentially develop novel therapeutic strategies.
"This study would not have been possible without the monumental team efforts of biologists, clinicians, and computational scientists," said lead author Wenbao Yu, PhD. "With their collaboration, we were able to gain new insights into the complex ecosystem of neuroblastoma."
The research was supported by a grant from the National Cancer Institute (NCI) Human Tumor Atlas Network (#U2C CA233285), as well as grants from the National Institutes of Health (NIH) (U54 HL165442), American Cancer Society Institutional Research Grant (IRG-22-150-41-IRG), and NIH (T32 CA009140).
This groundbreaking study, titled "Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring," was published online on April 14th, 2025 in Nature Genetics. The DOI for this article is 10.1038/s41588-025-02158-6.
0 Comments
Latest on The PennZone
- International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
- The Robert Travers Team of Long & Foster Marks 300+ Homes Sold, Expands Seller Representation
- CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
- RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
- Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
- MoMojo Records Signs Gary Nicholson
- Steve Weclew is Appointed by STS Capital Partners as Managing Director
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
- Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
- Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
- Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
- Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
- AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
- New Atlas Maps the 38 States Behind Every Conversation